- Home
- ILAG vs IMNN Comparison
ILAG vs IMNN Comparison
Compare ILAG & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- IMNN
- Stock Information
- Founded
- ILAG 1981
- IMNN 1982
- Country
- ILAG Hong Kong
- IMNN United States
- Employees
- ILAG N/A
- IMNN N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- IMNN Health Care
- Exchange
- ILAG Nasdaq
- IMNN Nasdaq
- Market Cap
- ILAG 10.7M
- IMNN 12.1M
- IPO Year
- ILAG 2022
- IMNN 1985
- Fundamental
- Price
- ILAG $0.55
- IMNN $6.53
- Analyst Decision
- ILAG
- IMNN Buy
- Analyst Count
- ILAG 0
- IMNN 2
- Target Price
- ILAG N/A
- IMNN $182.61
- AVG Volume (30 Days)
- ILAG 250.7K
- IMNN 244.8K
- Earning Date
- ILAG 04-28-2025
- IMNN 08-05-2025
- Dividend Yield
- ILAG N/A
- IMNN N/A
- EPS Growth
- ILAG N/A
- IMNN N/A
- EPS
- ILAG N/A
- IMNN N/A
- Revenue
- ILAG $7,506,551.00
- IMNN N/A
- Revenue This Year
- ILAG N/A
- IMNN N/A
- Revenue Next Year
- ILAG N/A
- IMNN N/A
- P/E Ratio
- ILAG N/A
- IMNN N/A
- Revenue Growth
- ILAG 16.50
- IMNN N/A
- 52 Week Low
- ILAG $0.34
- IMNN $4.83
- 52 Week High
- ILAG $1.35
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- ILAG 56.14
- IMNN 40.89
- Support Level
- ILAG $0.50
- IMNN $6.17
- Resistance Level
- ILAG $0.60
- IMNN $7.21
- Average True Range (ATR)
- ILAG 0.05
- IMNN 0.51
- MACD
- ILAG 0.00
- IMNN 0.14
- Stochastic Oscillator
- ILAG 41.14
- IMNN 20.45
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).